Clinical trials
Locally Advanced Gastric Cancer clinical trials
Below are recruiting locally advanced gastric cancer clinical trials, each written for real people, not researchers. We’re tracking 312 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04908566RecruitingPhase 2
PD-1 immunotherapy plus chemotherapy before and after gastric surgery
This trial studies whether adding a PD-1 immune therapy to chemotherapy around the time of surgery can improve outcomes for people with locally advanced stomach or stomach–esophagus junction cancer. It aims to better control the cancer before and reduce the chance it comes back after surgery.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06510010RecruitingPhase 2
Chemo plus H. pylori treatment for advanced stomach cancer
This trial tests whether adding H. pylori bacteria treatment to standard chemotherapy (before and after surgery) can improve outcomes for people with locally advanced stomach cancer. It combines oxaliplatin and S-1 chemo with antibiotics to clear the infection.
GuangzhouAges 18–75 - NCT06802666RecruitingPhase 2
Short radiation plus combo drugs for rectal cancer
This trial tests a new combination for rectal cancer that hasn't spread far: a short course of radiation followed by two drugs (AK112 and CAPOX). The goal is to shrink the tumor before surgery and possibly avoid more aggressive treatments.
HubeiAges 18–75 - NCT05699655RecruitingPhase 2/Phase 3
New pre-surgery treatment for advanced stomach cancer with immunotherapy
This trial tests a new combination (tislelizumab plus apatinib and chemotherapy) before surgery for certain advanced stomach cancers, compared with the standard chemotherapy plus S1. The goal is to shrink the tumor and improve outcomes before and around surgery.
Fuzhou, FujianAges 18–75 - NCT06830018Recruiting
New megestrol for advanced stomach or colon cancer with fatigue
This study tests a new form of megestrol (a medicine that can boost appetite and energy) for people with advanced stomach or colorectal cancer who also have fatigue and poor appetite. It is given as a first treatment, meaning you haven't had chemotherapy yet for your advanced cancer.
Shenyang, LiaoningAges 18–75 - NCT03961373RecruitingPhase 3
Standard vs longer lymph node surgery after chemo for stomach cancer
This study compares two surgical approaches to remove lymph nodes after you’ve already had chemotherapy for stomach cancer. It aims to see whether removing lymph nodes in a more extended way improves outcomes without causing unacceptable side effects.
SienaAges 18–80 - NCT06727981Recruiting
Immunotherapy as first treatment for stomach cancer
This trial tests immunotherapy as the first treatment for people with advanced or locally advanced stomach cancer. It may help if you haven't had any prior anti-cancer therapy and are starting treatment soon.
Jinan, ShandongAges 18–100 - NCT06023758RecruitingPhase 2
Study of two drugs with or without chemo for HER2-positive stomach cancer
This study tests two new immunotherapy drugs (KN026 and KN046) with or without chemotherapy (XELOX) for people with a specific type of advanced stomach cancer that makes too much HER2 protein. The goal is to see if this combination can shrink tumors or slow the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07298200RecruitingPhase 1
XH001 injection plus T-cells for advanced gastric cancer
This trial tests a new treatment combining an injection (XH001) with specially made immune cells (T-cells) that target your tumor's unique markers. It's for people with advanced stomach cancer who have not responded to standard therapies.
Nanjing, JiangsuAges 18–70 - NCT07325630RecruitingPhase 2
Perioperative study of IBI363 for MHC-II-negative advanced stomach cancer
This trial tests a new treatment called IBI363 given before and after surgery for people with a certain type of advanced stomach cancer that lacks the MHC-II marker. The goal is to see if it helps shrink the tumor and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT07259226RecruitingPhase 2
Studying resistance to antibody-drug conjugates in advanced cancer
This study is for people with advanced breast, bladder, lung, or stomach cancer who are about to start treatment with a type of targeted therapy called an antibody-drug conjugate (ADC). The trial will collect tumor samples and blood to understand how cancers become resistant to these drugs and to find better ways to predict treatment success.
VillejuifAges 18 years+ - NCT07103668RecruitingPhase 3
Study of a new drug for advanced stomach cancer after prior treatments
This trial tests an experimental therapy for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy targets a specific protein (CLDN18.2) found on cancer cells. The goal is to see if this approach can help control the disease.
BeijingAges 18 years+ - NCT06901531RecruitingPhase 3
Study of zolbetuximab with pembrolizumab and chemo for gastric cancer
This trial tests a new combination of drugs (zolbetuximab, pembrolizumab, and chemotherapy) for people with advanced stomach or gastroesophageal junction cancer. It may be an option if your tumor has certain proteins (CLDN18.2 and PD-L1) and you haven't had chemotherapy for advanced disease.
Birmingham, AlabamaAges 18 years+ - NCT07066657RecruitingPhase 1
Study of MRG007 for advanced solid tumors
This trial tests a new drug called MRG007 for people with advanced solid tumors that haven't responded to other treatments. The drug targets a protein called CDH17 on cancer cells; you need a tumor sample to check for it.
Los Angeles, CaliforniaAges 18 years+ - NCT06974110RecruitingPhase 1
Study of a new drug for advanced solid tumors with MSI-H or dMMR
This trial tests an oral medication called MOMA-341 in people with advanced solid tumors that have high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). It aims to see if the drug can help when prior immunotherapy hasn't worked or isn't available.
Phoenix, ArizonaAges 18 years+ - NCT06293898RecruitingPhase 1
Study of BL-M07D1 for HER2-positive solid tumors
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
Birmingham, AlabamaAges 18 years+ - NCT07692204RecruitingPhase 2
Testing a new drug for advanced stomach cancer
This trial tests a new study drug (SAR445877) for adults with advanced stomach or gastroesophageal junction cancer that has worsened after at least one prior treatment. It aims to find the best dose and see if the drug can help shrink or slow the cancer.
ShanghaiAges 18 years+ - NCT05705492RecruitingPhase 2
Olanzapine to help cancer-related weight and appetite loss
This Phase 2 trial tests whether olanzapine can help people with advanced cancer who are losing weight and not eating enough. It looks for improvements in appetite and weight while you receive your first-line palliative cancer treatment.
Portland, OregonAges 18 years+ - NCT03740256RecruitingPhase 1
HER2-targeted oncolytic virus plus custom immune cells for solid cancers
This Phase 1 study tests a treatment plan that combines a virus designed to attack cancer with your own custom immune cells that target HER2. It aims to shrink advanced HER2-positive solid tumors (and make future options safer/more effective).
Houston, TexasAges 18 years+ - NCT03787056Recruiting
Blood test marker study in many cancer types
This study measures a blood marker called progastrin (at diagnosis and during treatment) to see how well it predicts response or outcomes. It may help doctors choose or monitor treatment more precisely for several cancer types.
BronAges 18 years+ - NCT03825861RecruitingPhase 2
Before-surgery chemotherapy for locally advanced stomach cancer
This Phase 2 study tests chemotherapy given before surgery (called FOLFIRINOX) for people with locally advanced stomach cancer. The goal is to shrink the tumor and improve outcomes after the surgery plan is completed.
São PauloAges 18–75 - NCT04606446RecruitingPhase 2
Study drug for ER-positive, HER2-negative cancers after treatment
This Phase 2 study tests a new Pfizer medicine (PF-07248144) for certain advanced or metastatic breast, prostate, or lung cancers that have not responded to standard treatment or no standard options exist. You may qualify if you have a specific tumor type and a limited number of prior cancer treatments, and if your body functions (blood, liver, kidneys) and heart rhythm meet safety limits.
Scottsdale, ArizonaAges 18 years+ - NCT04850729Recruiting
Study links surgery medicines to the stomach tumor environment
This trial looks at how medicines given around the time of stomach cancer surgery may change the “tumor microenvironment,” which is the biology around the tumor. It may help doctors better understand which perioperative treatments work best for locally advanced, operable stomach cancer.
Guangzhou, GuangdongAges 18–75 - NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Orange, CaliforniaAges 18 years+
Hear when a new Locally Advanced Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced gastric cancer?
- Yes. Clin2 currently lists 312 recruiting locally advanced gastric cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced gastric cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced gastric cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.